Viral Load: Small Change by Sixth Day of Treatment Can Often Predict Poor Response

AIDS TREATMENT NEWS Issue #374, November 23, 2001
John S. James

A U.S. National Institutes of Health study of 124 pediatric and adult patients taking protease inhibitors for the first time found that the change in viral load in the first six days of the treatment was able to predict many cases of poor response of the regimen by week 12. Therefore treatment could be changed quickly in these cases (instead of at 4 or 8 weeks, as recommended by current U.S. guidelines), reducing the development of drug resistance by minimizing the time on an ineffective therapy.

In this study, "reduction in plasma HIV-1 of less than 0.72 log by day 6 after initiation of therapy predicted poor long-term responses in more than 99% of the patients." For those with less than a 0.96 log reduction, the chance of poor response at 12 weeks was 95%. But while very good at predicting some cases of drug failure, 6-day viral load was not as good at assuring long-term success. This is because unpredictable events can occur after day six, such as new mutations that cause viral resistance.

In clinical practice, some patients will not get their blood drawn on exactly the sixth day. Presumably the cut- off value for counting drug failure should be adjusted if the second blood draw is at, for example, 7 days, although the paper did not discuss this. However, this study found that samples taken at day 13 or day 28 were not as predictive as those taken at day 6 -- probably because of the more complex factors affecting viral load after the initial period of rapid decline.

Prediction may be better if there is also a viral load test on day 3, 4, or 5 -- due to natural fluctuations of viral levels, and also due to the variability of test results. The researchers did not seem to think that this extra test would be necessary in clinical practice.

This research team previously reported that the trough (lowest) drug concentration in blood plasma at the end of the first week, but not the dose, correlated with viral decline, and predicted long-term response. But it would be hard to measure blood levels of three or more drugs, or to know how sensitive the virus was to them. The authors suggest that the much simpler measurement of early viral load change is good enough.

Comment

Physicians might want to look at viral load decline by day six of certain new treatments -- in order to quickly change a clearly ineffective regimen. But the patients and treatments in this study were often not representative of what physicians see today. We hope the guidelines committees will study all the available information, and decide if a day-six viral load test should now be recommended for patients starting or changing antiretroviral therapy -- or if additional studies should be done first.

011123
ATN37401

Copyright © 2001 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org  http://www.aidsnews.org

Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Feedback/Contact Us.